Exelixis Inc (EXEL) 1.76 $EXEL
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18
Business Wire - Tue Nov 11, 3:40PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York. The Exelixis presentation is scheduled for 9:10 a.m. EST/6:10 a.m. PST on Tuesday, November 18, 2014.
EXEL: 1.76 (-0.05)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.53 (+0.27), GSK: 45.66 (+0.04), NVS: 94.38 (+1.72), EXEL: 1.76 (-0.05)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.91 (-0.01), CRIS: 1.31 (+0.01), IMMU: 3.80 (-0.09), PCYC: 137.80 (+0.43), ONCY: 0.78 (-0.06), PFE: 30.42 (unch), LLY: 67.68 (+0.28), BMY: 57.80 (-0.81), GSK: 45.66 (+0.04), JNJ: 109.07 (+0.32), SNTA: 3.23 (-0.13), NVS: 94.38 (+1.72), XLRN: 35.31 (+1.52), ARRY: 3.68 (-0.13), CELGZ: 3.18 (+0.05), EXEL: 1.76 (-0.05)
Update: Exelixis Reports Q3 Earnings - Impact To My Thesis
Christopher F. Davis - at Seeking Alpha - Fri Nov 07, 3:42AM CST
EXEL: 1.76 (-0.05)
Exelixis completes enrollment in cabozantinib Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:31AM CST
EXEL: 1.76 (-0.05)
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
Business Wire - Thu Nov 06, 5:01AM CST
-- Primary Analysis of PFS Endpoint to Be Conducted on First 375 Patients Enrolled --
EXEL: 1.76 (-0.05)
Hot Stock: Exelixis, Shares Gain 10.9% (EXEL)
Comtex SmarTrend(R) - Wed Nov 05, 11:38AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.9% to $1.83 on 1.1x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's 0.5%) and outperformed the S&P 500 (10.9% to the S&P's 0.4%) during today's trading.
EXEL: 1.76 (-0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 23.22 (-0.88), AWAY: 30.97 (+0.17), PHMD: 2.33 (-0.13), ROYT: 9.55 (-0.33), VG: 3.72 (-0.02), MEMP: 15.36 (-0.90), MACK: 8.39 (-0.16), ATVI: 20.33 (-0.08), NUS: 39.72 (-0.65), SSYS: 101.11 (-0.96), EOG: 95.85 (-1.71), CLNY: 24.67 (-0.01), CRTO: 38.20 (+0.92), IBIO: 1.08 (-0.03), NICE: 46.40 (+0.02), VPCO: 1.91 (+0.34), ZU: 28.68 (+0.07), EXEL: 1.76 (-0.05), ANV: 1.20 (+0.07), FEYE: 33.34 (+0.19), JIVE: 6.93 (+0.26), TRIP: 69.02 (-1.36), WLT: 2.86 (-0.20), YOD: 2.56 (-0.09), CHUY: 22.25 (-0.24), ANR: 2.42 (-0.20), NG: 2.75 (-0.05), AEZS: 0.59 (-0.02), ARIA: 6.25 (-0.22), CTSH: 53.39 (+0.15)
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:42PM CST
EXEL: 1.76 (-0.05)
Exelixis' Cometriq Makes a Comeback
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 7:40PM CST
Exelixis rose 10% in after-hours trading Tuesday after releasing third-quarter earnings, but the increase had nothing to do with the revenue it generated. Sales of its only approved drug, Cometriq, came it at just $6.3 million in the third...
NVS: 94.38 (+1.72), EXEL: 1.76 (-0.05)
Exelixis tops 3Q profit forecasts
Automated Insights - Tue Nov 04, 6:21PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $62.6 million in its third quarter.
EXEL: 1.76 (-0.05)
Exelixis (EXEL) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
EXEL: 1.76 (-0.05)
Exelixis beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:34PM CST
EXEL: 1.76 (-0.05)
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Business Wire - Tue Nov 04, 3:14PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis' collaboration with the NCI. Joel Neal, M.D., Ph.D., from ECOG-ACRIN member institution Stanford University/Stanford Cancer Institute, chairs the study.
EXEL: 1.76 (-0.05)
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 04, 3:13PM CST
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
EXEL: 1.76 (-0.05)
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 1:04PM CST
EXEL data by YCharts What: Shares of Exelixis , a biopharmaceutical company focused on developing therapies targeted at cancer, rallied 11% in October, based on data from S&P Capital IQ , as investors' nerves calmed down from the month...
EXEL: 1.76 (-0.05)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.05), ITRI: 40.92 (-0.72), AWAY: 30.97 (+0.17), OKE: 55.65 (-0.81), HR: 25.84 (+0.10), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.64 (+0.01), ADEP: 8.66 (-0.28), CBSO: 31.08 (+0.27), NSTG: 12.19 (+0.03), MITT: 19.03 (-0.15), CRTO: 38.20 (+0.92), FOXA: 34.99 (+0.35), OKS: 47.88 (-0.10), JMBA: 12.70 (-0.02), IVR: 16.26 (+0.04), CSU: 23.42 (+0.42), MYGN: 33.35 (+0.36), JIVE: 6.93 (+0.26), GAS: 51.65 (-0.47), COUP: 16.00 (-0.01), NRP: 12.58 (-0.25), MOSY: 1.79 (+0.12), COHR: 58.14 (-0.74), DOX: 47.58 (-0.12), CKEC: 28.48 (+0.08), OAS: 25.72 (-0.65), PAYC: 22.60 (+0.25), PCYC: 137.80 (+0.43), AXLL: 42.99 (-0.24), NP: 57.67 (-0.27), BIRT: 3.69 (-0.11), ATVI: 20.33 (-0.08), EXAM: 37.73 (+0.04), P: 18.45 (-0.34), JAZZ: 172.98 (-0.55), PBPB: 13.61 (-0.09), EXEL: 1.76 (-0.05), CERS: 4.42 (+0.23), DVN: 63.28 (-0.79), FEYE: 33.34 (+0.19), CHUY: 22.25 (-0.24), FRGI: 56.43 (-0.24), GHDX: 32.77 (-0.22), PACD: 6.69 (-0.18), BIO: 111.54 (-0.39), BIOL: 2.34 (-0.03), JKHY: 60.50 (-0.33), KAR: 33.74 (+0.09), CDXS: 2.30 (-0.10), MPO: 2.94 (-0.25), FANG: 64.76 (-0.05), CORT: 3.05 (-0.01), CALD: 15.63 (-0.01)
Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 241.63 (+1.01), HSP: 58.09 (unch), EXEL: 1.76 (-0.05)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 87.92 (+0.97), LXRX: 1.33 (-0.06), AMGN: 160.85 (-1.08), REGN: 402.63 (+1.52), EXEL: 1.76 (-0.05)
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
Business Wire - Tue Oct 14, 3:12PM CDT
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 1.76 (-0.05)
Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18
Business Wire - Tue Nov 11, 3:40PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York. The Exelixis presentation is scheduled for 9:10 a.m. EST/6:10 a.m. PST on Tuesday, November 18, 2014.
EXEL: 1.76 (-0.05)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.53 (+0.27), GSK: 45.66 (+0.04), NVS: 94.38 (+1.72), EXEL: 1.76 (-0.05)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.91 (-0.01), CRIS: 1.31 (+0.01), IMMU: 3.80 (-0.09), PCYC: 137.80 (+0.43), ONCY: 0.78 (-0.06), PFE: 30.42 (unch), LLY: 67.68 (+0.28), BMY: 57.80 (-0.81), GSK: 45.66 (+0.04), JNJ: 109.07 (+0.32), SNTA: 3.23 (-0.13), NVS: 94.38 (+1.72), XLRN: 35.31 (+1.52), ARRY: 3.68 (-0.13), CELGZ: 3.18 (+0.05), EXEL: 1.76 (-0.05)
Update: Exelixis Reports Q3 Earnings - Impact To My Thesis
Christopher F. Davis - at Seeking Alpha - Fri Nov 07, 3:42AM CST
EXEL: 1.76 (-0.05)
Exelixis completes enrollment in cabozantinib Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:31AM CST
EXEL: 1.76 (-0.05)
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
Business Wire - Thu Nov 06, 5:01AM CST
-- Primary Analysis of PFS Endpoint to Be Conducted on First 375 Patients Enrolled --
EXEL: 1.76 (-0.05)
Hot Stock: Exelixis, Shares Gain 10.9% (EXEL)
Comtex SmarTrend(R) - Wed Nov 05, 11:38AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.9% to $1.83 on 1.1x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's 0.5%) and outperformed the S&P 500 (10.9% to the S&P's 0.4%) during today's trading.
EXEL: 1.76 (-0.05)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST
TTPH: 23.22 (-0.88), AWAY: 30.97 (+0.17), PHMD: 2.33 (-0.13), ROYT: 9.55 (-0.33), VG: 3.72 (-0.02), MEMP: 15.36 (-0.90), MACK: 8.39 (-0.16), ATVI: 20.33 (-0.08), NUS: 39.72 (-0.65), SSYS: 101.11 (-0.96), EOG: 95.85 (-1.71), CLNY: 24.67 (-0.01), CRTO: 38.20 (+0.92), IBIO: 1.08 (-0.03), NICE: 46.40 (+0.02), VPCO: 1.91 (+0.34), ZU: 28.68 (+0.07), EXEL: 1.76 (-0.05), ANV: 1.20 (+0.07), FEYE: 33.34 (+0.19), JIVE: 6.93 (+0.26), TRIP: 69.02 (-1.36), WLT: 2.86 (-0.20), YOD: 2.56 (-0.09), CHUY: 22.25 (-0.24), ANR: 2.42 (-0.20), NG: 2.75 (-0.05), AEZS: 0.59 (-0.02), ARIA: 6.25 (-0.22), CTSH: 53.39 (+0.15)
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:42PM CST
EXEL: 1.76 (-0.05)
Exelixis' Cometriq Makes a Comeback
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 7:40PM CST
Exelixis rose 10% in after-hours trading Tuesday after releasing third-quarter earnings, but the increase had nothing to do with the revenue it generated. Sales of its only approved drug, Cometriq, came it at just $6.3 million in the third...
NVS: 94.38 (+1.72), EXEL: 1.76 (-0.05)
Exelixis tops 3Q profit forecasts
Automated Insights - Tue Nov 04, 6:21PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $62.6 million in its third quarter.
EXEL: 1.76 (-0.05)
Exelixis (EXEL) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST
EXEL: 1.76 (-0.05)
Exelixis beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:34PM CST
EXEL: 1.76 (-0.05)
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Business Wire - Tue Nov 04, 3:14PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis' collaboration with the NCI. Joel Neal, M.D., Ph.D., from ECOG-ACRIN member institution Stanford University/Stanford Cancer Institute, chairs the study.
EXEL: 1.76 (-0.05)
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 04, 3:13PM CST
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
EXEL: 1.76 (-0.05)
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 1:04PM CST
EXEL data by YCharts What: Shares of Exelixis , a biopharmaceutical company focused on developing therapies targeted at cancer, rallied 11% in October, based on data from S&P Capital IQ , as investors' nerves calmed down from the month...
EXEL: 1.76 (-0.05)
Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:35PM CST
AMRS: 2.88 (-0.05), ITRI: 40.92 (-0.72), AWAY: 30.97 (+0.17), OKE: 55.65 (-0.81), HR: 25.84 (+0.10), NYMT: 8.11 (-0.01), OCLR: 1.68 (+0.03), ENPH: 10.64 (+0.01), ADEP: 8.66 (-0.28), CBSO: 31.08 (+0.27), NSTG: 12.19 (+0.03), MITT: 19.03 (-0.15), CRTO: 38.20 (+0.92), FOXA: 34.99 (+0.35), OKS: 47.88 (-0.10), JMBA: 12.70 (-0.02), IVR: 16.26 (+0.04), CSU: 23.42 (+0.42), MYGN: 33.35 (+0.36), JIVE: 6.93 (+0.26), GAS: 51.65 (-0.47), COUP: 16.00 (-0.01), NRP: 12.58 (-0.25), MOSY: 1.79 (+0.12), COHR: 58.14 (-0.74), DOX: 47.58 (-0.12), CKEC: 28.48 (+0.08), OAS: 25.72 (-0.65), PAYC: 22.60 (+0.25), PCYC: 137.80 (+0.43), AXLL: 42.99 (-0.24), NP: 57.67 (-0.27), BIRT: 3.69 (-0.11), ATVI: 20.33 (-0.08), EXAM: 37.73 (+0.04), P: 18.45 (-0.34), JAZZ: 172.98 (-0.55), PBPB: 13.61 (-0.09), EXEL: 1.76 (-0.05), CERS: 4.42 (+0.23), DVN: 63.28 (-0.79), FEYE: 33.34 (+0.19), CHUY: 22.25 (-0.24), FRGI: 56.43 (-0.24), GHDX: 32.77 (-0.22), PACD: 6.69 (-0.18), BIO: 111.54 (-0.39), BIOL: 2.34 (-0.03), JKHY: 60.50 (-0.33), KAR: 33.74 (+0.09), CDXS: 2.30 (-0.10), MPO: 2.94 (-0.25), FANG: 64.76 (-0.05), CORT: 3.05 (-0.01), CALD: 15.63 (-0.01)
Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 241.63 (+1.01), HSP: 58.09 (unch), EXEL: 1.76 (-0.05)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 87.92 (+0.97), LXRX: 1.33 (-0.06), AMGN: 160.85 (-1.08), REGN: 402.63 (+1.52), EXEL: 1.76 (-0.05)
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
Business Wire - Tue Oct 14, 3:12PM CDT
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 1.76 (-0.05)
